Literature DB >> 15240621

Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency.

Vivien S Bonert1, Janet D Elashoff, Philip Barnett, Shlomo Melmed.   

Abstract

GH secretion is decreased in obese subjects, whereas age-adjusted IGF-I concentrations are normal. This study was undertaken to rigorously delineate the extent of obesity [elevated body mass index (BMI)] associated with decreased somatotrope secretory function resulting in apparent adult GH deficiency. The peak GH response evoked by combined arginine (0.5 g/kg infused iv over 30 min) and GHRH (1 microg/kg iv bolus) was measured in 59 healthy male subjects with BMIs ranging from normal to obese. BMI correlated with the peak evoked GH response (Pearson r = -0.59; P < 0.01), and the percentage of subjects exhibiting an abnormal evoked GH response, i.e. less than 9 ng/ml, increased from 5% for those with a BMI less than 25 (normal), to 13% for those with a BMI of 25-26.9 (mildly overweight), to 33% for those with a BMI of 27-29.9 (moderately overweight), and to 64% for those with a BMI of 30 or more (obese). BMI is a major determinant of evoked adult GH response to provocative testing. The diagnosis of adult GH deficiency using the evoked GH response in patients with even mild BMI elevation does not accurately distinguish normal from deficient responses and may result in the erroneous classification of obese subjects as GH deficient and thus unnecessarily requiring GH replacement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240621     DOI: 10.1210/jc.2003-032213

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

Review 1.  The Link Between Inadequate Sleep and Obesity in Young Adults.

Authors:  Perla A Vargas
Journal:  Curr Obes Rep       Date:  2016-03

Review 2.  Diagnosis of adult growth hormone deficiency: still a matter of debate.

Authors:  F Camanni
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

Review 3.  Anterior pituitary hormone replacement therapy--a clinical review.

Authors:  Christoph J Auernhammer; George Vlotides
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

4.  GH secretion in a cohort of children with pseudohypoparathyroidism type Ia.

Authors:  L de Sanctis; J Bellone; M Salerno; E Faleschini; M Caruso-Nicoletti; M Cicchetti; D Concolino; A Balsamo; F Buzi; L Ghizzoni; C de Sanctis
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

5.  Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Authors:  Hideo Makimura; Meghan N Feldpausch; Alison M Rope; Linda C Hemphill; Martin Torriani; Hang Lee; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2012-09-26       Impact factor: 5.958

6.  The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Authors:  Hideo Makimura; Caitlin A Murphy; Meghan N Feldpausch; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

7.  Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study.

Authors:  Daniel F Kelly; Charlene Chaloner; Diana Evans; Amy Mathews; Pejman Cohan; Christina Wang; Ronald Swerdloff; Myung-Shin Sim; Jihey Lee; Mathew J Wright; Claudia Kernan; Garni Barkhoudarian; Kevin C J Yuen; Kevin Guskiewicz
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

8.  Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity.

Authors:  Hideo Makimura; Takara Stanley; David Mun; Cindy Chen; Jeffrey Wei; Jean M Connelly; Linda C Hemphill; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

Review 9.  Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS).

Authors:  Ioannis Karamouzis; Loredana Pagano; Flavia Prodam; Chiara Mele; Marco Zavattaro; Arianna Busti; Paolo Marzullo; Gianluca Aimaretti
Journal:  Endocrine       Date:  2015-11-16       Impact factor: 3.633

10.  Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity.

Authors:  Takara L Stanley; Meghan N Feldpausch; Caitlin A Murphy; Steven K Grinspoon; Hideo Makimura
Journal:  Growth Horm IGF Res       Date:  2013-11-15       Impact factor: 2.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.